Pfizer reports moderate side effects in COVID-19 vaccine trials

The independent data monitoring committee reviewing the study did not express safety concerns

Pfizer - Pfizer reports moderate side effects in COVID-19 vaccine trials

Pfizer Inc. (NYSE:PFE) said one the COVID-19 vaccines developed with BioNTech (NASDAQ:BNTX) gave mild-to-moderate side effects to participants in clinical trials.

These included fatigue, headache, chills and muscle pain, Reuters reported, while some volunteers also developed fevers, including a few high fevers.

READ: The runners in the COVID-19 vaccine race

Some were given the vaccine and some a placebo, though the blinded nature of the study means Pfizer cannot identify who has received what.

Kathrin Jansen, Pfizer’s head of vaccine research and development, highlighted the independent data monitoring committee reviewing the study did not express safety concerns, despite having access to the blidned data.

Late-stage studies are underway on over 29,000 people out of the 44,000 required for the trial. Over 12,000 received the second dose.

The pair could have 100mln dose ready by the end of the year, with the ability to supply 1.3bn doses by the end of next year.

Quick facts: Pfizer

Price: 36.05 USD

Market: NYSE
Market Cap: $200.33 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Cabral Gold adds 2nd drill rig as company identifies new high-grade veins

Cabral Gold (CVE: CBR-OTC: CBGZF) CEO Alan Carter joined Steve Darling from Proactive Vancouver with news the company has identified at least six new NE trending high-grade veins in the Machichie SW area located immediately north of the MG deposit. Carter telling Proactive what had led them...

1 day, 14 hours ago

2 min read